Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

20.54 +0.11 (+0.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 291,299
Open 20.76
Bid (Size) 18.85 (1)
Ask (Size) 21.84 (1)
Prev. Close 20.43
Today's Range 20.13 - 21.11
52wk Range 12.54 - 27.24
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033... 
Via Benzinga
In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics
Via Benzinga

Performance

YTD
+11.39%
+11.39%
1 Month
-15.75%
-15.75%
3 Month
-11.16%
-11.16%
6 Month
-18.94%
-18.94%
1 Year
-3.93%
-3.93%

More News

Read More
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
The Latest Analyst Ratings For Bicycle Therapeutics
Via Benzinga
Expert Ratings For Bicycle Therapeutics
Via Benzinga
The Analyst Landscape: 4 Takes On Bicycle Therapeutics
Via Benzinga
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Gold Falls Sharply; US Composite PMI Surges In May
Via Benzinga
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
From Bicycle Therapeutics plc
Via Business Wire
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Two Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present at the AACR Annual Meeting 2024
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.